All News

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Findings show that 81% of posts related to cancer on the social media platform TikTok touted fake cures.

I share how faith, positive affirmations and resilience helped me overcome stage 2 colon cancer and find strength in recovery.

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.

Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.

As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.

An expert explains the importance of getting a second opinion during a cancer journey.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors.

At my routine oncology checkup, I regretted not bringing my husband when an unexpected medication changes left me feeling overwhelmed and alone.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.

After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.

The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.

When I recognize my frustration and dissapointment with the test results for my chronic lymphocytic leukemia, I find comfort in listening to music.

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve outcomes versus chemotherapy.

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with relapsed/refractory osteosarcoma.

Both laparoscopic wedge and endoscopic resection are safe and feasible treatment approaches for patients with gastric gastrointestinal stromal tumors.

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and my hopes for the future.

Low-dose oral minoxidil, the hair growth drug that is the active ingredient in Rogaine, may be safe and effective for patients with breast cancer.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.